Trial Outcomes & Findings for A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU (NCT NCT02003053)

NCT ID: NCT02003053

Last Updated: 2018-09-07

Results Overview

The number of patients tolerating Inspiratory Muscle Training or Sham.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

7 participants

Primary outcome timeframe

Baseline and until participant is extubated or discharged from the critical care unit (up to 1 month post-baseline)

Results posted on

2018-09-07

Participant Flow

Participant milestones

Participant milestones
Measure
Inspiratory Muscle Training
In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge. Inspiratory Muscle Trainer
Sham
In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge. Inspiratory Muscle Trainer
Overall Study
STARTED
4
3
Overall Study
COMPLETED
4
3
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Inpsiratory Muscle Training
n=4 Participants
In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge. Inspiratory Muscle Trainer
Sham
n=3 Participants
In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge. Inspiratory Muscle Trainer
Total
n=7 Participants
Total of all reporting groups
Age, Continuous
49.0 years
STANDARD_DEVIATION 16.9 • n=4 Participants
54.33 years
STANDARD_DEVIATION 3.78 • n=3 Participants
51.29 years
STANDARD_DEVIATION 11.28 • n=7 Participants
Sex: Female, Male
Female
NA Participants
n=4 Participants
NA Participants
n=3 Participants
NA Participants
n=7 Participants
Sex: Female, Male
Male
NA Participants
n=4 Participants
NA Participants
n=3 Participants
NA Participants
n=7 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
United States
4 participants
n=4 Participants
3 participants
n=3 Participants
7 participants
n=7 Participants

PRIMARY outcome

Timeframe: Baseline and until participant is extubated or discharged from the critical care unit (up to 1 month post-baseline)

The number of patients tolerating Inspiratory Muscle Training or Sham.

Outcome measures

Outcome measures
Measure
Inspiratory Muscle Training
n=4 Participants
In the IMT group, inspiratory muscle training will start with 30% of MIP, for five minutes twice a day with increments of 10 % (absolute) everyday. Supplemental oxygen will be given as needed. The exercise will be done seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge. Inspiratory Muscle Trainer
Sham
n=3 Participants
In the SHAM group, sham device will be used to train subjects 5 minutes twice a day, seven days a week until patient achieves liberation from mechanical ventilation or ICU/CCU discharge. Inspiratory Muscle Trainer
Safety and Feasibility of Inspiratory Muscle Training
3 Participants
3 Participants

Adverse Events

Inspiratory Muscle Training Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Sham Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Peter Morris

University of Kentucky

Phone: 8593235045

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place